Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05299749 · ClinicalTrials.gov registry record · NA
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
A NA study of Schizophrenia and Treatment-resistant Schizophrenia, sponsored by Boston VA Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT05299749: Recruiting NA study of Schizophrenia and Treatment-resistant Schizophrenia, sponsored by Boston VA Research Institute.
NCT05299749 is a NA study of Schizophrenia and Treatment-resistant Schizophrenia that is actively recruiting participants, run by Boston VA Research Institute. The registered enrollment target is 104 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05299749, a NA study of Schizophrenia and Treatment-resistant Schizophrenia, is actively recruiting participants, sponsored by Boston VA Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Primary Outcome
does real-time fMRI neurofidback reduce BOLD activity in STG, post NFB
Conditions Studied
Interventions
- OTHER stg-rt-fMRI-Neurofeeback
- OTHER sham-rt-fMRI-Neurofeedback
Study Locations (1)
Massachusetts
- Boston VA Healthcare System, Brockton - Brockton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05299749 shows while recruiting
NCT05299749 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which stg-rt-fMRI-Neurofeeback is the first listed.
NCT05299749 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05299749 about?
NCT05299749 is a clinical study titled "Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations". Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
What is the current status of trial NCT05299749?
This trial is currently recruiting. It is a NA study. The enrollment target is 104 participants. The study started on 2022-03-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05299749 study?
This clinical trial studies the following conditions: Schizophrenia, Treatment-resistant Schizophrenia, Auditory Hallucination.
What interventions are being tested in trial NCT05299749?
The interventions under investigation include: stg-rt-fMRI-Neurofeeback (OTHER), sham-rt-fMRI-Neurofeedback (OTHER).
Who is sponsoring clinical trial NCT05299749?
This trial is sponsored by Boston VA Research Institute, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05299749 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05299749's enrollment target sits among peer trials
104 136th of 315 higher than 179 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI